Top Injectable Manufacturer in Togo – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 2 days ago
- 10 min read
Last Updated: August 23, 2026
TL;DR: Togo regulates medicines through the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), a directorate of the Ministry of Health rather than an autonomous agency, operating under the 2009 Public Health Code (Loi n° 2009-007 of 15 May 2009). That is changing: a decree creating an autonomous Agence togolaise de régulation pharmaceutique was still under final review at a Kpalimé expert workshop in late July 2026, so DPML remains the operative authority today. Registration dossiers follow ICH CTD format, are filed on paper with the Ministry, and Togo's own government service portal lists the processing time and validity period as "N/A" — there is no published timeline. Togo is not a party to the 1961 Hague Apostille Convention, so Indian Certificates of Pharmaceutical Product and GMP certificates require the full consular legalization chain rather than a single apostille. Public-sector supply runs through CAMEG-Togo, the non-profit central purchasing body created in August 1998, which buys through prequalified-supplier tenders, while universal health insurance has been rolling out since 1 January 2024 under INAM and CNSS. Malaria dominates the disease burden — WHO estimates 2.37 million cases and 3,486 deaths in 2024 — alongside rising hypertension at 27.4% of adults, of whom 90.7% take no medication. France supplies roughly 58% of Togo's pharmaceutical imports against India's 17%, and India's Ministry of External Affairs has recorded a Togolese delegation seeking to buy medicines directly from India because most currently route through French distribution networks. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, supports Togolese importers, CAMEG and institutional buyers with CTD/ACTD-ready documentation and a realistic legalization timeline.
Key Takeaways
The Direction de la Pharmacie, du Médicament et des Laboratoires (DPML), a directorate of Togo's Ministry of Health — now the Ministry of Health, Public Hygiene, Universal Health Coverage and Insurance — registers medicines under the 2009 Public Health Code, and the African Union's AMRH country profile records that Togo's applications must be submitted in ICH CTD format, with registration fees in the EUR 150-300 range. Applications go to the Minister of Health in three paper copies; the government's own service portal states the process is not yet digitized and lists both the processing time and the validity period as "N/A". Import authorizations are quicker and better documented at 3-10 days with 90-day validity. Farbe Firma prepares CTD/ACTD technical files and plans Togo submissions around published requirements rather than assumed regional norms.
Togo is not a Contracting Party to the 1961 Hague Apostille Convention — verified directly against the HCCH status table, where Togo does not appear — so the apostille shortcut India enjoys with many markets does not apply here. Indian Certificates of Pharmaceutical Product, WHO-GMP certificates, free-sale certificates and powers of attorney all require the full consular legalization chain: notarization, Ministry of External Affairs attestation in India, then legalization by the Togolese diplomatic mission accredited to India. This is a real lead-time cost, and Farbe Firma's regulatory team builds it into every Togo-bound timeline from the outset rather than discovering it mid-registration.
Togo is rebuilding its regulatory architecture right now, which makes this an unusually good moment to enter. A draft decree creating an autonomous Agence togolaise de régulation pharmaceutique was under final expert review in July 2026; Lomé hosted the 17th West African Medicines Regulatory Harmonization Steering Committee in June 2026, which adopted a WA-MRH Sustainability Plan for 2026-2030; and Togo takes over the Director-Generalship of the West African Health Organisation in January 2027. Note that the WA-MRH joint assessment produces a regional recommendation only — each national authority still issues its own marketing authorization, so a regional route does not replace registration with DPML. WHO has published no Global Benchmarking Tool maturity level for Togo, and Togo does not appear on WHO's March 2026 list of authorities operating at ML3 or ML4.
Disease burden keeps injectable demand structurally high. WHO's World Malaria Report 2025 estimates 2,371,693 malaria cases and 3,486 deaths in Togo in 2024, with incidence down about a third since 2015, and Togo's national programme reports malaria accounting for roughly 40% of outpatient consultations. Maternal mortality stands at 349 per 100,000 live births (2023), tuberculosis incidence at 48 per 100,000 with treatment coverage of only 69%, and HIV prevalence at 1.6% of adults with about 94,600 people on antiretroviral therapy. Noncommunicable disease is climbing fast: the WHO STEPS survey of 2021 found hypertension in 27.4% of adults — 51.1% among those aged 45-69 — with 90.7% of hypertensive adults taking no medication at all, and diabetes at 4.9%, nearly double the 2010 figure.
Introduction: Why an Injectable Manufacturer in Togo Must Meet Global Standards
Togo, home to 8.1 million people according to the November 2022 census, sits almost exactly at the epidemiological crossover point: WHO's Global Health Estimates attribute 45.5% of deaths to communicable, maternal, perinatal and nutritional causes and 43.5% to noncommunicable disease. That balance is precisely what makes the country demanding for suppliers. An injectable manufacturer in Togo has to serve a malaria and maternal-health caseload that runs through public facilities in high volume while simultaneously supplying the cardiovascular, anti-infective and metabolic injectables that a rapidly growing noncommunicable-disease burden requires. With about 64% of current health expenditure still paid out of pocket by households and fewer than one physician per 10,000 people, reliability and price discipline are not soft preferences here — they determine whether a product reaches a patient at all.
Farbe Firma Pvt Ltd, operating from Gujarat, India as a WHO-GMP certified sterile injectable manufacturer, produces more than 100 injectable formulations inside ISO Class 5 aseptic filling suites and exports to more than 30 countries under CTD and ACTD dossier formats. Serving Togo well means preparing a CTD-format dossier that DPML can review against its published requirements, planning honestly around a full consular legalization chain because Togo is not an Apostille Convention member, and understanding that the practical route to public-sector volume runs through CAMEG-Togo's prequalified-supplier tenders rather than through open bidding. Farbe Firma treats these as one integrated timeline rather than three separate problems discovered in sequence.
What Sets a World-Class Injectable Manufacturer in Togo Apart
Any credible injectable manufacturer in Togo has to work through DPML, which sits inside the Ministry of Health rather than operating as an autonomous agency, under the framework of the 2009 Public Health Code. The African Union's AMRH country profile confirms that applications are made in ICH CTD format, with fees indicatively in the EUR 150-300 range, and Togo's official government service portal sets out the mechanics plainly: the application goes to the Minister of Health in three paper copies, the process is not yet dematerialized, and both the execution time and the validity period are published as "N/A". That absence of a published timeline is itself the most useful planning fact available — it means a manufacturer should confirm current requirements directly with DPML rather than assume the five-year renewable norm common elsewhere in Francophone West Africa applies automatically to Togo.
The institutional buying landscape is equally specific. CAMEG-Togo, created in August 1998 as a non-profit association with management autonomy and licensed as a pharmaceutical wholesaler, holds a public-service mandate under a 2010 convention to supply the National Essential Medicines List to public and non-profit facilities at a social price. It distributes around 167 essential health products routinely plus roughly 100 further products bought on specific request, and it purchases through restricted international tenders open only to preselected suppliers — meaning prequalification is the gate, and a manufacturer that has not been preselected cannot bid at all. Alongside CAMEG, universal health insurance under Loi n° 2021-022 has been deploying since 1 January 2024 through INAM for public-sector and vulnerable groups and CNSS for private, informal and agricultural workers, with INAM publishing its own database of reimbursable pharmaceutical products. Togo has not published consolidated coverage figures, so the scheme is best treated as scaling rather than complete.
Quality Systems Behind Every Batch We Ship to Togo
Every batch leaving Farbe Firma's Gujarat facility for Togo passes through the same analytical panel we apply globally. Identity, assay and related-substance testing run on validated HPLC and GC methods benchmarked against USP, BP, IP and EP monographs, Karl Fischer titration confirms residual moisture in lyophilized and powder-fill products, and every sterile lot undergoes sterility testing and bacterial endotoxin (LAL) testing, alongside sub-visible particulate counts, pH, osmolality and fill-volume verification. This is the certificate-of-analysis and validation documentation a DPML reviewer expects to see referenced in a CTD-format dossier, and it is the same evidence base a CAMEG prequalification assessment examines when deciding whether a supplier and product pair can be admitted to its restricted tenders.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions using Zone IVb hot-and-humid parameters appropriate to Togo's coastal and Sahelian climate range, with photostability assessed per ICH Q1B, so shelf-life claims hold up from the port of Lomé through onward distribution to all six health regions and 39 health districts. Because Togo is not an Apostille Convention member, our regulatory team plans the full legalization chain — notarization, Ministry of External Affairs attestation in India, then legalization by the Togolese mission accredited to India — into the registration schedule from day one, since this documentation step, not the technical dossier, is usually the longest pole in a Togo launch.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Togo for Global Buyers
Togo's disease burden creates sustained and overlapping streams of injectable demand. WHO's World Malaria Report 2025 estimates 2,371,693 malaria cases and 3,486 deaths in 2024, and although incidence has fallen roughly a third since 2015, the national malaria programme still reports malaria accounting for about 40% of outpatient consultations and a quarter of hospital admissions — a caseload that sustains steady demand for injectable antimalarials and supportive critical-care products. Maternal mortality at 349 per 100,000 live births (2023) keeps obstetric injectables, oxytocics and anti-infectives in continuous demand, while tuberculosis incidence of 48 per 100,000 with treatment coverage of only 69% means roughly three in ten cases are still not reached. Layered on top, the WHO STEPS survey of 2021 found hypertension in 27.4% of adults with 90.7% untreated and diabetes at 4.9%, nearly double the 2010 rate — a noncommunicable-disease curve that will reshape Togo's injectable demand over the coming decade.
For manufacturers and brand owners, Farbe Firma also functions as a CDMO/CMO partner, offering private-label sterile injectables built on the same WHO-GMP, ISO Class 5 platform with CTD/ACTD-format technical files. The gap in Togo's local supply is specific and worth stating precisely. Togo now has two pharmaceutical plants: FHC Médica, opened at the Adétikopé Industrial Platform in April 2025 with capacity for 750 million tablets and 150 million capsules a year, and Do Pharma at Avéta, producing around 18 million bottles of intravenous solutions annually since 2018. Neither covers small-volume sterile injectables, ampoules and vials of complex generics, or lyophilized products — which is exactly the category an overseas sterile-injectable specialist is placed to serve. The former president of Togo's national pharmacists' body has put overall import dependence at close to 90%, and supply into the country runs through only about six importer-distributors including CAMEG.
The commercial opening here is unusually well documented on both sides. UN Comtrade mirror data puts Togo's pharmaceutical imports at about USD 120 million in 2024, with France supplying roughly 58% against India's 17%, and India's Ministry of External Affairs records in its own country brief that a Togolese delegation led by the Director of Procurement came to discuss "procurement of medicines directly into Togo as currently most of the medicines are routed through French distribution networks." Trade data and diplomacy independently agree on the same point. India has since hosted both CAMEG's Director General and a DPML official at its Ministry of Health's policymakers' visit in June 2025. It is worth being candid about scale: Togo is not among India's top 25 pharmaceutical export destinations, and India's pharmaceutical exports to Africa actually fell 0.42% in FY2024-25 while global exports grew 9.40%. That makes Togo a market to be built deliberately rather than assumed, and Farbe Firma's export team builds every Togo quote, dossier and delivery schedule around exactly that reality.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Togo?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries. Our documentation is prepared in CTD and ACTD formats, which matches the ICH CTD dossier format recorded for Togo by the African Union's AMRH country profile for submissions to the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML).
How does injectable product registration work in Togo?
Medicines are registered by DPML, a directorate of the Ministry of Health operating under the 2009 Public Health Code rather than as an autonomous agency, using ICH CTD-format dossiers with fees indicatively in the EUR 150-300 range. Applications are submitted to the Minister of Health in three paper copies and the process is not yet digitized. Togo's official service portal publishes neither a processing time nor a validity period, so confirm current requirements directly with DPML. Import authorizations are separately documented at 3-10 days with 90-day validity. A decree creating an autonomous Agence togolaise de régulation pharmaceutique was still under review as of July 2026.
Do we need a local importer or partner to sell injectables in Togo?
Yes. Import into Togo runs through a small set of licensed importer-distributors — around six in total, including CAMEG-Togo — and a locally licensed partner is required. For public-sector volume, CAMEG-Togo purchases through restricted international tenders limited to preselected suppliers on the ACAME model, so supplier and product prequalification is the actual gate to bidding. A partner who understands both DPML registration and CAMEG prequalification is worth considerably more than one who knows only the first.
Which injectables are in strongest demand in Togo?
Malaria remains dominant, with WHO estimating 2.37 million cases and 3,486 deaths in 2024 and the national programme reporting malaria at roughly 40% of outpatient consultations, sustaining demand for injectable antimalarials and supportive critical-care products. Maternal health drives obstetric and anti-infective injectable demand given maternal mortality of 349 per 100,000 live births. Tuberculosis and HIV add anti-infective volume, and a fast-rising noncommunicable-disease burden — hypertension at 27.4% of adults with 90.7% untreated — is expanding cardiovascular and metabolic demand. Farbe Firma's 100+ product range covers all of these categories.
What documentation and logistics considerations matter most for a Togo launch?
The single most important one is that Togo is not a party to the Hague Apostille Convention, so an apostille will not be accepted. Indian Certificates of Pharmaceutical Product and GMP certificates need the full consular legalization chain: notarization, Ministry of External Affairs attestation in India, then legalization by the Togolese mission accredited to India. Plan this as the longest step, not the technical dossier. Commercially, plan around CAMEG-Togo's prequalification-based tendering, the ongoing rollout of universal health insurance through INAM and CNSS since January 2024, and the fact that around 64% of health spending still comes directly out of household pockets.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments